Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer’s disease, in which twisted clumps of a protein called tau accumulate in the brain. Cells near those clumps begin to die after tau accumulates, but growing evidence suggests that much of the damage doesn’t come from the protein directly.

Adults with hard-to-treat epilepsy who used cannabis most days had more than twice as many convulsive seizures per year and more rapidly became resistant to antiseizure medications compared with nonusers, according to new research from Washington University School of Medicine in St. Louis. The study appears in the journal Epilepsia.

RNA vaccines and other nucleic acid therapeutics are typically packaged within fatty molecules known as lipid nanoparticles (LNPs). MIT researchers have now come up with a way to produce these particles much more quickly, and with more precise control over their size and shape.

Minutes count when a patient with a stroke arrives at the hospital emergency room. Doctors stand ready to treat, but whether the blood clot can be removed medically depends on what medication the patient is already taking. Even if a blood sample is rushed through the laboratory, results can take up to an hour to arrive.

Streptococcus pneumoniae is a bacterial pathogen that causes life-threatening infections, including pneumonia and meningitis. These infections are commonly treated with antibiotics, but antibiotics are becoming less effective against S. pneumoniae over time due to changes in the pathogen that cause drug resistance. This phenomenon, called antimicrobial resistance, is resulting in significant healthcare costs and deaths around the world.

The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects,